CA-BOEHRINGER-INGELHEIM
9.1.2023 17:01:41 CET | Business Wire | Press release
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune cell-targeting compounds, further strengthening the company’s pipeline.
Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients. 3T‘s platform aims to address this challenge by identifying novel shared T-cell receptor (TCR) targets of productive immune responses and comprehensively screening TCRs and TCR mimetics for specificity and off-target cross-reactivities. The platform identifies the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning. This may lead to tumor-specific, safer therapies that can be delivered at higher doses.
“At Boehringer Ingelheim, we are committed to transforming patients’ lives. Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology + Immune Modulation, Boehringer Ingelheim.
“On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. “3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumor indications and across patient populations.”
Under the agreement, Boehringer Ingelheim will provide patient-derived TCR data to fuel 3T’s target discovery efforts to identify antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones totaling $268 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
For the full press release and link to “Notes to Editors” please click here:
Press Release
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005420/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meet Yuvo - The All-In-One Platform Helping Travel Brands Optimize Every Stage of Their Customer's Journey15.10.2026 14:36:00 CEST | Press release
The multi-service travel tech company gives OTAs, TMCs, airlines, insurers and fintechs one integration to add real-time flight data, disruption protection and travel add-ons to every trip. Yuvo data shows that flight disruption hit more than 913 million passengers in 2025, and travellers are now buying travel protection at six times the pre-pandemic rate. Yet for most travel brands, a delayed flight still means support calls, refunds and lost customers. Yuvo turns those moments, and every other step of the trip, into revenue and loyalty. Most travel brands earn from their customers only once: when they book. Yuvo changes that. It helps partners earn across the whole journey, with no technology to build and full control of the customer relationship. Yuvo works with some of the biggest names in travel, turning the customer relationships they already have into an ongoing revenue stream while keeping them fully in control. Built by a team of seasoned travel tech experts, the platform has
Visa Direct Launches Stablecoin-Powered Money Movement as Pilots Move to Production15.10.2026 14:00:00 CEST | Press release
Inyo Global becomes the first enabler to bring Visa Direct's stablecoin-enabled prefunding into production, making stablecoin-powered money movement available for businesses that run cross-border payments through Visa Direct. Today, Visa (NYSE: V) announced the next phase of its stablecoin strategy as Visa Direct stablecoin capabilities advance from pilot stage to commercial deployment. The milestone marks an important step in bringing stablecoin-enabled money movement into real-world commercial operations. In the initial rollout, Inyo Global, a Visa Direct processor, is the first enabler of this new offering, powering it for eligible Visa Direct clients and partners1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015116414/en/ Over the past year, Visa Direct has worked with clients and partners to explore how stablecoins can help improve the way businesses fund and move money across borders. As interest in faster, more
TreviPay Named a Leader in Two 2026 IDC MarketScape Assessments for AI-Enabled A/R Automation and Embedded Payments15.10.2026 14:00:00 CEST | Press release
TreviPay, a global B2B payments infrastructure partner, today announced it has been named a Leader in two 2026 IDC MarketScape assessments: the IDC MarketScape: Worldwide AI-Enabled Accounts Receivable Automation Applications for the Enterprise 2026 Vendor Assessment and the IDC MarketScape: Worldwide Embedded Payment Applications in Accounts Receivable Workflows 2026 Vendor Assessment. The recognition comes as enterprise finance teams look beyond automating individual A/R tasks toward coordinating the decisions and actions that drive growth and improve cash flow. We believe these assessments reflect a market in which payment execution, cash application, credit, collections and customer experience are valued when working together in one connected system. The IDC MarketScape for Worldwide AI-Enabled Accounts Receivable Automation Applications for the Enterprise noted the following strengths: Flexible risk retention options: A partnership with Mastercard lets clients offer net terms with
Philip Morris International Announces EU Economic Footprint Study 2021-2025: Transformation Made in Europe15.10.2026 13:42:00 CEST | Press release
The company contributed nearly €343 billion to the EU economy, including €22.3 billion directed to European suppliers, €27.4 billion invested across its European operations, and €39.5 billion in exports, while PMI's European value chain supported a growing number of jobs, reaching nearly 164,000 in 2025 At a defining moment for Europe’s competitiveness, Philip Morris International Inc. (PMI) (NYSE: PM) today publishes the second edition of its EU Economic Footprint Study, prepared by EY-Parthenon. Spanning 2021 to 2025, the study demonstrates the scale of PMI’s contribution across the European Union and the capabilities developed through its transformation. The company’s footprint reaches far beyond its own operations, supporting suppliers, manufacturers, researchers, retailers, farmers, employees, and communities across Europe. Five key figures from the EU Economic Footprint Study 2021-2025: Nearly €343 billion in total contribution to the EU economy between 2021 and 2025. €22.3 billi
Future Health Launches Global Challenge to Move Health Innovation Towards Real-world Application15.10.2026 13:26:00 CEST | Press release
The Future Health Digital Innovation Challenge 2026 invites entrants to develop AI, software, and connected technology solutions across fertility, population health, and wellbeingSelected teams will gain access to technical and clinical expertise across Abu Dhabi’s health and innovation ecosystem, alongside structured support to refine solutions, test assumptions and develop working prototypes, helping them turn promising ideas into real-world impact fasterSelected solutions may also progress to further validation, incubation, piloting and scale, while three finalists will also share a total prize pool of USD 105,000 at an awards ceremony at GITEX 2026The programme connects global innovation with Abu Dhabi’s clinical, health-system, and technology expertiseInception42, MBZUAI, and Microsoft join as co-creators in the Challenge Future Health – A Global Initiative by Abu Dhabi opened applications for the Future Health Digital Innovation Challenge 2026, welcoming innovators from around th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom